Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:00 PM
Ignite Modification Date: 2025-12-25 @ 12:46 PM
NCT ID: NCT01536795
Description: None
Frequency Threshold: 0
Time Frame: 90 Days
Study: NCT01536795
Study Brief: A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
WR279,396 With Tegaderm Dressing 24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing 0 None 0 24 16 24 View
WR279,396 With Gauze and Tape Dressing 24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only). WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days 0 None 0 24 7 24 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Vertigo SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (Unspecified) View
Local reaction (infection at biopsy site) SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Edema SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Any infection and infestation SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (Unspecified) View
Erysipelas SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (Unspecified) View
Any investigations SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Blood creatinine increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Blister (vesicles) SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (Unspecified) View
Dermatitis contact (allergy to Tegaderm) SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (Unspecified) View
Erythema SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (Unspecified) View